Related references
Note: Only part of the references are listed.Re: 'Colistin plus meropenem for carbapenem-resistant gram-negative infections: in vitro synergism is not associated with better clinical outcomes'-Author's reply
A. Nutman et al.
CLINICAL MICROBIOLOGY AND INFECTION (2020)
Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteria
A. N. Kristoffersson et al.
CLINICAL MICROBIOLOGY AND INFECTION (2020)
High incidence of MDR and XDR Pseudomonas aeruginosa isolates obtained from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial
Astrid Perez et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Colistin Use in Patients with Chronic Kidney Disease: Are We Underdosing Patients?
Luisa Sorli et al.
MOLECULES (2019)
International Consensus Guidelines for the Optimal Use of the Polymyxins Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)
Brian T. Tsuji et al.
PHARMACOTHERAPY (2019)
Colistin for the treatment of urinary tract infections caused by extremely drug-resistant Pseudomonas aeruginosa: Dose is critical
Luisa Sorli et al.
JOURNAL OF INFECTION (2019)
Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial
Marin H. Kollef et al.
LANCET INFECTIOUS DISEASES (2019)
Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial
Antoni Torres et al.
LANCET INFECTIOUS DISEASES (2018)
Active monotherapy and combination therapy for extensively drug-resistant Pseudomonas aeruginosa pneumonia
Thana Khawcharoenporn et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2018)
Dosing Guidance for Intravenous Colistin in Critically Ill Patients
Roger L. Nation et al.
CLINICAL INFECTIOUS DISEASES (2017)
Pharmacokinetic/Toxicodynamic Analysis of Colistin-Associated Acute Kidney Injury in Critically Ill Patients
Alan Forrest et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance
Ghady Haidar et al.
CLINICAL INFECTIOUS DISEASES (2017)
Impact of colistin plasma levels on the clinical outcome of patients with infections caused by extremely drug-resistant Pseudomonas aeruginosa
Luisa Sorli et al.
BMC INFECTIOUS DISEASES (2017)
Updated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform?
Roger L. Nation et al.
CLINICAL INFECTIOUS DISEASES (2016)
Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections
Ryan K. Shields et al.
CLINICAL INFECTIOUS DISEASES (2016)
Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations
David van Duin et al.
CLINICAL INFECTIOUS DISEASES (2016)
Validation of a colistin plasma concentration breakpoint as a predictor of nephrotoxicity in patients treated with colistin methanesulfonate
Juan P. Horcajada et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2016)
New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection
Soon-Ee Cheah et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance
Scott T. Micek et al.
CRITICAL CARE (2015)
Comparison of Intrapulmonary and Systemic Pharmacokinetics of Colistin Methanesulfonate (CMS) and Colistin after Aerosol Delivery and Intravenous Administration of CMS in Critically Ill Patients
Matthieu Boisson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study
Luisa Sorli et al.
BMC INFECTIOUS DISEASES (2013)
Prevalence of Multidrug-Resistant Pseudomonas aeruginosa and Carbapenem-Resistant Enterobacteriaceae Among Specimens From Hospitalized Patients With Pneumonia and Bloodstream Infections in the United States From 2000 to 2009
Marya D. Zilberberg et al.
JOURNAL OF HOSPITAL MEDICINE (2013)
Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of Patients
S. M. Garonzik et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Colistin Penetration in the Alveolar Lining Fluid of Critically III Patients Treated With IV Colistimethate Sodium
Nikolaos Markou et al.
CHEST (2011)
Elucidation of the Pharmacokinetic/Pharmacodynamic Determinant of Colistin Activity against Pseudomonas aeruginosa in Murine Thigh and Lung Infection Models
Rajesh V. Dudhani et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Pharmacokinetic/Pharmacodynamic Investigation of Colistin against Pseudomonas aeruginosa Using an In Vitro Model
Phillip J. Bergen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Steady-State Pharmacokinetics and BAL Concentration of Colistin in Critically Ill Patients After IV Colistin Methanesulfonate Administration
Roberto Imberti et al.
CHEST (2010)
Population Pharmacokinetic Analysis of Colistin Methanesulfonate and Colistin after Intravenous Administration in Critically Ill Patients with Infections Caused by Gram-Negative Bacteria
D. Plachouras et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Effectiveness and Safety of Colistin for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections
M. Montero et al.
INFECTION (2009)
CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting
Teresa C. Horan et al.
AMERICAN JOURNAL OF INFECTION CONTROL (2008)
The RIFLE criteria and mortality in acute kidney injury: A systematic review
Z. Ricci et al.
KIDNEY INTERNATIONAL (2008)
Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate
Andrew S. Levey et al.
ANNALS OF INTERNAL MEDICINE (2006)
Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa
PK Linden et al.
CLINICAL INFECTIOUS DISEASES (2003)
A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography
J Li et al.
JOURNAL OF CHROMATOGRAPHY B (2001)
Share Paper
